Last $8.76 USD
Change Today -0.03 / -0.34%
Volume 809.8K
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

amicus therapeutics inc (FOLD) Snapshot

Open
$8.77
Previous Close
$8.79
Day High
$8.77
Day Low
$8.41
52 Week High
01/8/15 - $9.63
52 Week Low
04/16/14 - $1.77
Market Cap
833.8M
Average Volume 10 Days
902.6K
EPS TTM
$-0.89
Shares Outstanding
95.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMICUS THERAPEUTICS INC (FOLD)

amicus therapeutics inc (FOLD) Related Bloomberg News

View More Bloomberg News

amicus therapeutics inc (FOLD) Related Businessweek News

No Related Businessweek News Found

amicus therapeutics inc (FOLD) Details

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company’s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.

92 Employees
Last Reported Date: 03/3/14
Founded in 2002

amicus therapeutics inc (FOLD) Top Compensated Officers

Chairman and Chief Executive officer
Total Annual Compensation: $824.1K
President and Chief Operating Officer
Total Annual Compensation: $475.0K
Chief Financial Officer and Secretary
Total Annual Compensation: $445.1K
Compensation as of Fiscal Year 2013.

amicus therapeutics inc (FOLD) Key Developments

Amicus Therapeutics, Inc. Announces Resignation of James Barrett from the Board of Directors, Effective March 1, 2015

On February 25, 2015, M. James Barrett informed Amicus Therapeutics, Inc. that he has chosen to resign from the Board of Directors effective March 1, 2015.

Amicus Therapeutics, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

Amicus Therapeutics, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

Amicus Therapeutics Announces Additional Positive Phase 3 Fabry Data on Patient Reported Outcomes at WORLDSymposium(TM) 2015

Amicus Therapeutics announced positive data on pre-specified patient reported outcomes from both of its Phase 3 studies of the oral small molecule pharmacological chaperone migalastat HCl for Fabry disease at WORLDSymposium 2015 in Orlando, Florida. The company previously reported positive Phase 3 data in both treatment (Study 011 [2], or FACETS) and enzyme replacement therapy (ERT) switch patients (Study 012 [3], or ATTRACT). Results from these studies have shown that treatment with migalastat has resulted in reductions in disease substrate, stability of kidney function and improvement in a key cardiac parameter (left ventricular mass index, or LVMi) in patients with amenable mutations. Pre-specified secondary and tertiary endpoints on patient-reported outcome measures from both Phase 3 studies are being reported for the first time at WORLDSymposium 2015. Study 011 was a Phase 3 study designed to measure the reduction of disease substrate (globotriaosylceramide, or GL-3) following treatment with migalastat in Fabry patients with amenable mutations. The study also measured clinical outcomes, including renal function and LVMi, as secondary endpoints. The 24-month study began with a 6-month double-blind, placebo-controlled treatment period, after which all patients were treated with migalastat for a 6-month open-label follow-up period and a subsequent 12-month open-label extension phase.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FOLD:US $8.76 USD -0.03

FOLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FOLD.
View Industry Companies
 

Industry Analysis

FOLD

Industry Average

Valuation FOLD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 446.4x
Price/Book 16.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 476.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMICUS THERAPEUTICS INC, please visit www.amicustherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.